OTCMKTS:CYBN Cybin (CYBN) Stock Price, News & Analysis $7.17 -0.43 (-5.66%) As of 08/14/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsBuy This Stock About Cybin Stock (OTCMKTS:CYBN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cybin alerts:Sign Up Key Stats Today's Range$7.04▼$7.5750-Day Range$7.17▼$9.0052-Week Range$4.81▼$13.88Volume470,725 shsAverage Volume315,302 shsMarket Capitalization$169.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. Read More Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address CYBN Stock News HeadlinesCybin CEO to Speak at Canaccord Genuity Growth ConferenceAugust 6, 2025 | tipranks.comCybin Inc. Expands Market Strategy with New SEC FilingJuly 14, 2025 | tipranks.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Cybin Inc. Secures $50 Million in Convertible Debenture DealJuly 10, 2025 | tipranks.comCybin Inc. Reports on Governance and ComplianceJuly 7, 2025 | tipranks.comCybin Inc. Advances Mental Health Innovations with Strategic Partnerships and Clinical ProgressJune 30, 2025 | tipranks.comCybin Secures $500 Million Financing to Boost Clinical ProgramsJune 30, 2025 | tipranks.comCybin to Participate in the 2025 Psychedelic Science ConferenceJune 11, 2025 | financialpost.comFSee More Headlines CYBN Stock Analysis - Frequently Asked Questions How have CYBN shares performed this year? Cybin's stock was trading at $8.82 at the start of the year. Since then, CYBN shares have decreased by 18.7% and is now trading at $7.17. How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cybin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and Company Calendar Today8/14/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYBN CIK1833141 Webwww.cybin.com Phone(866) 292-4601FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-93.17% Return on Assets-84.68% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book37.74Miscellaneous Outstanding Shares23,590,000Free Float170,213,000Market Cap$169.14 million OptionableNot Optionable Beta0.68 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:CYBN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.